This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2012
  • /
  • 09
  • /
  • EC approves Inlyta (Pfizer) for Real Cell Carcinom...
Drug news

EC approves Inlyta (Pfizer) for Real Cell Carcinoma

Read time: 1 mins
Last updated:5th Sep 2012
Published:5th Sep 2012
Source: Pharmawand
The European Commission (EC) has granted marketing authorization for Inlyta (axitinib) from Pfizer for the treatment of adult patients with advanced Renal Cell Carcinoma a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine. The Inlyta data demonstrates a statistically significant improvement in progression free survival compared with sorafenib, and supports the continued role for VEGFR-targeted therapy, following the first-line standard of care,Sutent.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.